LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer will be presenting at the Raymond James 45th Annual Institutional Investors Conference in Orlando, Florida today, Monday, March 4, 2024 at 3:25 p.m. Eastern Time.
A live webcast of RadNet's presentation can be accessed through the following link, https://wsw.com/webcast/rj129/rdnt/1616960 and is available for replay viewing. The Raymond James 45th Annual Institutional Investors Conference will take place at the JW Marriott Grande Lakes, Orlando.
Details for RadNet's Presentation: | |
Date: Time: Location: | Monday, March 4th, 2024 3:25 p.m. Eastern Time JW Marriott Grande Lakes, Orlando, FL |
About RadNet, Inc.
RadNet, Inc., is the leading national provider of free-standing, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 366 owned and/or operated outpatient imaging centers. RadNet's markets include California, Maryland, Delaware, New Jersey, New York, Florida, and Arizona. Together with affiliated radiologists, including full-time and per diem employees and technologists, RadNet has over 9,700 employees.
For more information, visit http://www.radnet.com.
Contact:
RadNet, Inc.
Mark Stolper, Executive Vice President and Chief Financial Officer
310-445-2800
Last Trade: | US$73.81 |
Daily Change: | 2.09 2.91 |
Daily Volume: | 522,027 |
Market Cap: | US$5.680B |
September 26, 2025 September 08, 2025 August 07, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load